09 CeoMeeting- Session 4- Sentinext

1,025 views

Published on

Session 4: Health & Wellness

Title: The Changing Face Of Healthcare:
Where Are The Opportunities?

Mr Peter Wulff, Sentinext Therapeutics

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,025
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

09 CeoMeeting- Session 4- Sentinext

  1. 1. CEO’s Life Sciences Conference Kuala Lumpur, October 2009
  2. 2. <ul><li>Founded by Prof. Jane Cardosa and Mr. Peter Wulff </li></ul><ul><li>Investment of RM 40 million from MLSCF and MTDC </li></ul><ul><li>First Phase focusing on Vaccine against EV71 </li></ul><ul><li>Additional programs to start in JEV, dengue and malaria </li></ul><ul><li>Strong team of employees behind Sentinext with experience from: </li></ul><ul><ul><li>Vaccine research and Virology </li></ul></ul><ul><ul><li>Clinical development </li></ul></ul><ul><ul><li>Process development & manufacturing </li></ul></ul><ul><ul><li>Vaccine marketing </li></ul></ul><ul><ul><li>IP </li></ul></ul><ul><ul><li>Management </li></ul></ul>
  3. 3. <ul><li>Our Strategic Outlook : </li></ul><ul><ul><li>Favorable demographics for vaccine development in SE Asia and Asian economies. A growing urban population with unmet need. </li></ul></ul><ul><ul><li>Emerging disease burdens create new markets. Traditionally overlooked by Big Pharma. </li></ul></ul><ul><ul><li>Improving regulatory framework throughout Asia-harmonization with FDA and EMEA. </li></ul></ul><ul><ul><li>Opportunity for tremendous leverage from foundations, governments and NGOs. </li></ul></ul><ul><li>Our Strategy : </li></ul><ul><ul><li>Develop vaccines and therapeutics for emerging diseases; tropical infectious diseases. </li></ul></ul><ul><ul><li>Companion diagnostics through partnerships. </li></ul></ul><ul><ul><li>Develop initial products through Phase I/II then seek partnerships. </li></ul></ul><ul><ul><li>Use proven “best of class” technology, coupled with deep epidemiological understanding. </li></ul></ul><ul><ul><li>Seek leverage among foundations, governments and NGO’s for trial development. </li></ul></ul><ul><ul><li>IPO on European or Asian exchange to finance pipeline and provide exit for investors. </li></ul></ul>
  4. 4. <ul><li>Prof. Jane Cardosa </li></ul><ul><ul><li>Princeton, Columbia, D.Phil Oxford. Scripps. </li></ul></ul><ul><ul><li>Professor Univ. Malaysia Sarawak </li></ul></ul><ul><ul><li>Institute Director for Institute of Health and Community Medicine. </li></ul></ul><ul><ul><li>Formerly WHO Steering Committee for Flavivirus Vaccines, TDR SAC diagnostics, Paediatric Dengue Vaccine Initiative </li></ul></ul><ul><ul><li>SAB member: Gates Foundation “ Grand Challenges for Global Health”. </li></ul></ul><ul><ul><li>Founder of Venture Technologies: first company to develop diagnostics for Dengue Virus serology. </li></ul></ul><ul><li>Mr. Peter Wulff </li></ul><ul><ul><li>Organic Chemist, Patent Attorney Univ. Copenhagen. </li></ul></ul><ul><ul><li>Co-Founder, Neurosearch A/S </li></ul></ul><ul><ul><li>Co-Founder, Former CEO & President of Bavarian Nordic A/S </li></ul></ul><ul><ul><li>“ 2007 Biotech Builder of Year” for Denmark. </li></ul></ul>
  5. 5. <ul><li>Discovered in 1969 as a cause of frequent epidemics of neurological disease in children. </li></ul><ul><li>Severe infections (< 5 yrs old) lead to CNS complications: meningitis, brain stem encephalitis, poliomyelitis-like symptoms. Recent fatal cases suggest virulence increasing for EV71. </li></ul><ul><li>Severe neurogenic pulmonary oedema occurs with 80-90% mortality within 12-18 hours. </li></ul><ul><li>No known treatment or vaccine in development. </li></ul>Recent SE Asian Epidemics Sarawak 1997 Taiwan 1998 Australia 1999 Korea, Taiwan, Japan, Singapore, Malaysia 2000 Taiwan 2002 Taiwan 2003 Malaysia, Singapore 2003 Vietnam 2005 Malaysia, Singapore 2006 Vietnam 2007 China, Vietnam, Singapore, Taiwan 2008/9
  6. 6. <ul><li>Prevalent in South East Asia, Japan, China but present in US and Europe. </li></ul><ul><li>Travelers market likely as large as that for JEV. </li></ul><ul><li>High demand for vaccine in endemic market. </li></ul><ul><ul><li>Endemic market has strong middle class </li></ul></ul><ul><li>No other vaccine in clinical development. </li></ul><ul><li>Big pharma showing interest in EV71 as target. </li></ul>
  7. 7. <ul><li>The epidemiology shows that EV71 is best controlled by a vaccine. </li></ul><ul><li>The EV71 vaccine will be a VLP containing all the structural proteins. </li></ul><ul><li>We have been studying the cyclical pattern of outbreaks of EV71. </li></ul><ul><li>We can plan efficacy trials without timing risk. </li></ul><ul><li>Save time and cost. </li></ul>
  8. 8. <ul><li>Sentinext will be developed to master all necessary disciplines on its own. </li></ul><ul><li>Sentinext has already recruited an international organization. </li></ul><ul><li>Sentinext organization have a strong network within relevant international organizations. </li></ul><ul><li>Sentinext key employees have a long experience with working with CROs and CMOs in toxicology, animal trials, clinical trials, regulatory and manufacturing. </li></ul><ul><li>Sentinext has access to a strong network of consultants within manufacturing, clinical, regulatory, toxicology, animal testing, IP, litigation. </li></ul><ul><li>Sentinext founders have long experience in raising money for biotech in international financial markets </li></ul>
  9. 9. <ul><li>Jeremy Farrar , Oxford University’s Clinical Research Unit in Vietnam </li></ul><ul><ul><li>Many years of experience running clinical research and clinical trials in disease endemic countries </li></ul></ul><ul><li>Richard Kuhn , Purdue University, USA </li></ul><ul><ul><li>Leading scientist in structure-function aspects of viruses, including flaviviruses and enteroviruses </li></ul></ul><ul><li>Peter McMinn , Sydney University, Australia </li></ul><ul><ul><li>Clinical virologist, extensive experience in reverse genetics approaches to understanding MVE and EV71 pathogenesis. </li></ul></ul>
  10. 10. Programs in JEV, dengue and malaria to start

×